Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 49

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
Item 1.    Financial Statements

Immunocore Holdings plc

Condensed Consolidated Balance Sheets

(Unaudited) (In thousands, except share and per share data)

September 30,2025December 31,2024AssetsCurrent assetsCash and cash equivalents$498,413 $455,731 Marketable securities393,940 364,645 Accounts receivable, net75,880 63,009 Prepaid expenses and other current assets48,960 41,033 Inventory, net5,655 5,446 Total current assets1,022,848 929,864 Property and equipment, net9,433 10,092 Operating lease right of use assets, net39,397 37,643 Deferred tax assets, net14,333 14,790 Other non-current assets16,489 17,117 Total assets$1,102,500 $1,009,506 Liabilities and shareholders’ equityCurrent liabilitiesAccounts payable$22,956 $25,100 Accrued expenses and other current liabilities144,937 185,534 Deferred revenue, current582 — Operating lease liabilities, current1,878 1,547 Total current liabilities170,353 212,181 Accrued expenses, non-current96,604 — Deferred revenue, non-current 4,995 5,434 Operating lease liabilities, non-current41,397 40,162 Interest-bearing loans and borrowings392,587 391,013 Total liabilities705,936 648,790 Commitments and contingencies (Note 10)Shareholders’ equityOrdinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of September 30, 2025 and December 31, 2024, respectively, and 50,467,954 and 50,064,860 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. 135 135 Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024.1 1 Additional paid-in capital1,227,649 1,190,104 Acc